Slowing down diabetes in newly diagnosed patients: the CD3-antibody STUDY

Patients treated with this antibody shortly after diagnosis maintained, for at least 18 months, a higher insulin production than patients receiving a placebo. Patients in the placebo group had to gradually increase their insulin dose to keep blood sugar levels under optimal control. Patients who were administered the active product were able to maintain their insulin dose as low as at diagnosis.
This positive effect was particularly found in patients under age 27 at diagnosis and with a less pronounced beta cell loss at the time of diagnosis.
Side effects of treatment were transient and consisted of flu-like and mononucleosis-like symptoms.